{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T23:58:05Z","timestamp":1772495885676,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.intimp.2021.107511","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T09:28:01Z","timestamp":1619515681000},"page":"107511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Prophylactic administration of fingolimod (FTY720) ameliorated experimental autoimmune myasthenia gravis by reducing the number of dendritic cells, follicular T helper cells and antibody-secreting cells"],"prefix":"10.1016","volume":"96","author":[{"given":"Ying","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Ru","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Sheng","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2021.107511_b0005","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.intimp.2021.107511_b0010","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.4049\/jimmunol.172.4.2697","article-title":"Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats","volume":"172","author":"Baggi","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2021.107511_b0015","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s12264-019-00344-1","article-title":"Enhancement of T Follicular Helper Cell-Mediated Humoral Immunity Reponses During Development of Experimental Autoimmune Myasthenia Gravis","volume":"35","author":"Cui","year":"2019","journal-title":"Neuroscience bulletin"},{"key":"10.1016\/j.intimp.2021.107511_b0020","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.molimm.2018.01.005","article-title":"Toll-like receptor 9 antagonist suppresses humoral immunity in experimental autoimmune myasthenia gravis","volume":"94","author":"Zhang","year":"2018","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.intimp.2021.107511_b0025","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.mcn.2015.08.010","article-title":"Statin-modified dendritic cells regulate humoral immunity in experimental autoimmune myasthenia gravis","volume":"68","author":"Li","year":"2015","journal-title":"Molecular and cellular neurosciences"},{"key":"10.1016\/j.intimp.2021.107511_b0030","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.4049\/jimmunol.1500725","article-title":"Augmentation of Circulating Follicular Helper T Cells and Their Impact on Autoreactive B Cells in Myasthenia Gravis","volume":"197","author":"Zhang","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2021.107511_b0035","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180096","article-title":"Decreased expression of circulating Aire and increased Tfh\/Tfr cells in myasthenia gravis patients","volume":"38","author":"Zhao","year":"2018","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.intimp.2021.107511_b0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nri2217","article-title":"Germinal centres: role in B-cell physiology and malignancy","volume":"8","author":"Klein","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2021.107511_b0045","doi-asserted-by":"crossref","first-page":"208","DOI":"10.7164\/antibiotics.47.208","article-title":"Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite","volume":"47","author":"Fujita","year":"1994","journal-title":"The Journal of antibiotics"},{"key":"10.1016\/j.intimp.2021.107511_b0050","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.4049\/jimmunol.160.10.5037","article-title":"FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing","volume":"160","author":"Chiba","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2021.107511_b0055","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/(SICI)1521-4141(200005)30:5<1435::AID-IMMU1435>3.0.CO;2-O","article-title":"Immunosuppressant FTY720 inhibits thymocyte emigration","volume":"30","author":"Yagi","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2021.107511_b0060","doi-asserted-by":"crossref","first-page":"10907","DOI":"10.1073\/pnas.1832725100","article-title":"Rapid induction of medullary thymocyte phenotypic maturation and egress inhibition by nanomolar sphingosine 1-phosphate receptor agonist","volume":"100","author":"Rosen","year":"2003","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2021.107511_b0065","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2174\/138955707781387948","article-title":"FTY720: a most promising immunosuppressant modulating immune cell functions","volume":"7","author":"Zhang","year":"2007","journal-title":"Mini reviews in medicinal chemistry"},{"key":"10.1016\/j.intimp.2021.107511_b0070","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","article-title":"Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Lublin","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2021.107511_b0075","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1111\/j.1600-6143.2006.01404.x","article-title":"FTY720\/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study","volume":"6","author":"Mulgaonkar","year":"2006","journal-title":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"key":"10.1016\/j.intimp.2021.107511_b0080","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.016371","article-title":"Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke: A Pilot Trial","volume":"132","author":"Zhu","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.intimp.2021.107511_b0085","doi-asserted-by":"crossref","first-page":"18315","DOI":"10.1073\/pnas.1416166111","article-title":"Impact of an immune modulator fingolimod on acute ischemic stroke","volume":"111","author":"Fu","year":"2014","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2021.107511_b0090","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1248\/bpb.28.736","article-title":"A novel immunomodulator, FTY720, prevents development of experimental autoimmune myasthenia gravis in C57BL\/6 mice","volume":"28","author":"Kohno","year":"2005","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.intimp.2021.107511_b0095","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/eji.201747187","article-title":"S1P receptor antagonists fingolimod and siponimod do not improve the outcome of experimental autoimmune myasthenia gravis mice after disease onset","volume":"48","author":"Pelz","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2021.107511_b0100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/imr.12740","article-title":"T follicular helper cell heterogeneity: Time, space, and function","volume":"288","author":"Song","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2021.107511_b0105","first-page":"651","article-title":"Myasthenia gravis and related disorders: Pathology and molecular pathogenesis","volume":"1852","author":"Ha","year":"2015","journal-title":"BBA"},{"key":"10.1016\/j.intimp.2021.107511_b0110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jneuroim.2015.03.004","article-title":"IgG1 deficiency exacerbates experimental autoimmune myasthenia gravis in BALB\/c mice","volume":"281","author":"Huda","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.intimp.2021.107511_b0115","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1600-065X.2010.00940.x","article-title":"Plasma cell development and survival","volume":"237","author":"Oracki","year":"2010","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2021.107511_b0120","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1002\/1521-4141(200109)31:9<2726::AID-IMMU2726>3.0.CO;2-H","article-title":"Inflamed kidneys of NZB \/ W mice are a major site for the homeostasis of plasma cells","volume":"31","author":"Cassese","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2021.107511_b0125","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2021.107511_b0130","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1084\/jem.20061289","article-title":"Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism","volume":"203","author":"Kabashima","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2021.107511_b0135","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.20081886","article-title":"Follicular helper T cells are required for systemic autoimmunity","volume":"206","author":"Linterman","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2021.107511_b0140","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.coi.2008.03.016","article-title":"Plasma cell differentiation and survival","volume":"20","author":"Tarlinton","year":"2008","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.intimp.2021.107511_b0145","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/eji.200939531","article-title":"Memory B cells: effectors of long-lived immune responses","volume":"39","author":"Tangye","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2021.107511_b0150","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1084\/jem.20141432","article-title":"ICOS maintains the T follicular helper cell phenotype by down-regulating Kruppel-like factor 2","volume":"212","author":"Weber","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2021.107511_b0155","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.4049\/jimmunol.175.4.2340","article-title":"The role of ICOS in the CXCR5+ follicular B helper T cell maintenance in vivo","volume":"175","author":"Akiba","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2021.107511_b0160","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.3389\/fimmu.2018.03178","article-title":"Residual Activatability of Circulating Tfh17 Predicts Humoral Response to Thymodependent Antigens in Patients on Therapeutic Immunosuppression","volume":"9","author":"Dahdal","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2021.107511_b0165","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.immuni.2010.12.012","article-title":"Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion","volume":"34","author":"Morita","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2021.107511_b0170","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/cei.12475","article-title":"Quantitative T cell subsets profile in peripheral blood from patients with idiopathic inflammatory myopathies: tilting the balance towards proinflammatory and pro-apoptotic subsets","volume":"179","author":"Espinosa-Ortega","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2021.107511_b0175","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.4049\/jimmunol.1100853","article-title":"Cutting edge: dendritic cell-restricted antigen presentation initiates the follicular helper T cell program but cannot complete ultimate effector differentiation","volume":"187","author":"Goenka","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2021.107511_b0180","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.4049\/jimmunol.1301284","article-title":"B cell antigen presentation in the initiation of follicular helper T cell and germinal center differentiation","volume":"192","author":"Barnett","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2021.107511_b0185","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.celrep.2015.05.042","article-title":"CD8alpha(-) Dendritic Cells Induce Antigen-Specific T Follicular Helper Cells Generating Efficient Humoral Immune Responses","volume":"11","author":"Shin","year":"2015","journal-title":"Cell reports"},{"key":"10.1016\/j.intimp.2021.107511_b0190","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.4049\/jimmunol.1401842","article-title":"FTY720 Abrogates Collagen-Induced Arthritis by Hindering Dendritic Cell Migration to Local Lymph Nodes","volume":"195","author":"Han","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2021.107511_b0195","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1111\/j.1600-6143.2005.01085.x","article-title":"The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo","volume":"5","author":"Lan","year":"2005","journal-title":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"key":"10.1016\/j.intimp.2021.107511_b0200","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/eji.201445064","article-title":"IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis","volume":"45","author":"Schaffert","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2021.107511_b0205","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.mcn.2013.03.005","article-title":"Atorvastatin-modified dendritic cells in vitro ameliorate experimental autoimmune myasthenia gravis by up-regulated Treg cells and shifted Th1\/Th17 to Th2 cytokines","volume":"56","author":"Li","year":"2013","journal-title":"Molecular and cellular neurosciences"},{"key":"10.1016\/j.intimp.2021.107511_b0210","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri1886","article-title":"Competence and competition: the challenge of becoming a long-lived plasma cell","volume":"6","author":"Radbruch","year":"2006","journal-title":"Nat. Rev. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921001478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921001478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T18:52:50Z","timestamp":1727290370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921001478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":42,"alternative-id":["S1567576921001478"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107511","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylactic administration of fingolimod (FTY720) ameliorated experimental autoimmune myasthenia gravis by reducing the number of dendritic cells, follicular T helper cells and antibody-secreting cells","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107511","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107511"}}